Last reviewed · How we verify

NCT05639140

A Registered Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.

Status unknown Last updated 6 December 2022
What this trial tests

trial testing Data collection in Neurodegenerative Disorders in 500 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
1 July 2025
1 July 2025

Quick facts

Lead sponsorFujian Medical University Union Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2018
Primary completion1 July 2025
Estimated completion1 July 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Fujian Medical University Union Hospital

Who can join

Adults 30 to 80, any sex, with Neurodegenerative Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Color discrimination deficit is a common manifestation of Alzheimer's disease (AD). However, the pathophysiology of this dysfunction remains poorly understood. The aim of the present study was to evaluate color discrimination using the Farnsworth-Munsell 100 hue test in patients with AD and mild cognitive impairment (MCI), compared with age-matched control subjects. As a secondary aim, we evaluated whether the outcomes of these visual tests were associated with cognitive.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for Neurodegenerative Disorders

Currently open trials in the same condition.

Other Fujian Medical University Union Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05639140.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing